Gold is 2025’s best performer. UBS sees more upside
In a recent filing with the Securities and Exchange Commission, Sight Sciences , Inc. (NASDAQ:SGHT) reported that Manohar K. Raheja, the company's Executive Vice President of Research & Development, purchased 5,000 shares of common stock. The acquisition, which took place on December 6, 2024, was executed at a price of $3.85 per share, amounting to a total transaction value of $19,250. Following this purchase, Raheja now directly owns 111,000 shares of the company. The transaction was signed off by Jeremy Hayden, acting as Attorney-in-Fact for Raheja.
In other recent news, Sight Sciences Inc. has been experiencing significant developments. UBS initiated coverage of the medical device company, forecasting robust sales growth by 2026. The company is transitioning from its OMNI surgical solution for glaucoma to its TearCare Dry Eye solution, which is designed to treat a form of dry eye affecting over 11 million patients, representing a $2.5 billion market.
UBS analysts anticipate double-digit sales growth and margin expansion surpassing consensus estimates for 2026 and beyond. Sight Sciences has also reported a slight year-over-year revenue increase in its third-quarter earnings call, with surgical glaucoma revenue accounting for $18.6 million. Despite a sequential decrease of 8% in surgical glaucoma revenue and a 4% decline in dry eye revenue, the company remains optimistic about growth in these segments in 2025.
Sight Sciences is contesting the final 2025 Medicare payment rule, which did not grant device-intensive status to OMNI procedures. The company also appointed Dr. MK Raheja as Executive Vice President of Research and Development to advance their surgical glaucoma pipeline. These are among the recent developments in Sight Sciences' journey towards anticipated growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.